MX340172B - Formulaciones estables de una enzima degradadora de hialuronano. - Google Patents
Formulaciones estables de una enzima degradadora de hialuronano.Info
- Publication number
- MX340172B MX340172B MX2013014923A MX2013014923A MX340172B MX 340172 B MX340172 B MX 340172B MX 2013014923 A MX2013014923 A MX 2013014923A MX 2013014923 A MX2013014923 A MX 2013014923A MX 340172 B MX340172 B MX 340172B
- Authority
- MX
- Mexico
- Prior art keywords
- hyaluronan
- degrading enzyme
- stable formulations
- formulations
- stable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 101100178973 Homo sapiens SPAM1 gene Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 1
- 229940099552 hyaluronan Drugs 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520962P | 2011-06-17 | 2011-06-17 | |
| PCT/US2012/042816 WO2012174478A2 (en) | 2011-06-17 | 2012-06-15 | Stable formulations of a hyaluronan-degrading enzyme |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014923A MX2013014923A (es) | 2014-02-11 |
| MX340172B true MX340172B (es) | 2016-06-28 |
Family
ID=46513830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014923A MX340172B (es) | 2011-06-17 | 2012-06-15 | Formulaciones estables de una enzima degradadora de hialuronano. |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2720712B1 (enExample) |
| JP (3) | JP2014518216A (enExample) |
| KR (2) | KR20140043438A (enExample) |
| CN (2) | CN103974715A (enExample) |
| AU (2) | AU2012271359B2 (enExample) |
| BR (1) | BR112013032396A2 (enExample) |
| CA (1) | CA2839511C (enExample) |
| EA (2) | EA201400031A1 (enExample) |
| ES (1) | ES2566549T3 (enExample) |
| IL (1) | IL229749A0 (enExample) |
| MX (1) | MX340172B (enExample) |
| NZ (2) | NZ618331A (enExample) |
| WO (1) | WO2012174478A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| BR112014016195A2 (pt) | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| RU2019128331A (ru) * | 2013-02-04 | 2019-12-16 | Санофи | Стабилизированные фармацевтические составы аналогов инсулина и/или производные инсулина |
| TWI641381B (zh) * | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| TW201605489A (zh) * | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| JP6562902B2 (ja) * | 2014-03-28 | 2019-08-21 | テルモ株式会社 | 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| CN104095871A (zh) * | 2014-07-10 | 2014-10-15 | 青岛蔚蓝生物股份有限公司 | 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液 |
| WO2016011262A1 (en) | 2014-07-16 | 2016-01-21 | New York University | Use of hyaluronidase for treatment of muscle stiffness |
| AR102869A1 (es) * | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN105018457A (zh) * | 2015-07-20 | 2015-11-04 | 宁波美成生物科技有限公司 | 虫荧光素酶稳定剂 |
| CN114835797A (zh) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| WO2018045943A1 (zh) * | 2016-09-06 | 2018-03-15 | 杏辉天力（杭州）药业有限公司 | 茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途 |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| CN108070532A (zh) * | 2016-11-16 | 2018-05-25 | 福建力多利生物科技有限公司 | 一种生产葡萄糖氧化酶的方法 |
| WO2019050749A1 (en) * | 2017-09-08 | 2019-03-14 | Eli Lilly And Company | PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL |
| CN107918020B (zh) * | 2017-11-15 | 2019-01-01 | 浙江夸克生物科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒 |
| JP7204729B2 (ja) | 2018-07-25 | 2023-01-16 | アルテオゼン インコーポレイテッド | 新規なヒアルロン酸加水分解酵素変異体およびそれを含む薬学組成物 |
| JP7728176B2 (ja) * | 2019-03-15 | 2025-08-22 | イーライ リリー アンド カンパニー | 保存製剤 |
| CN110592056A (zh) * | 2019-09-19 | 2019-12-20 | 昆明理工大学 | 噬菌体裂解酶复合粉剂及其制备方法和应用 |
| CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
| CN113840921A (zh) * | 2020-01-23 | 2021-12-24 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| CN120738156A (zh) | 2020-08-07 | 2025-10-03 | 阿特根公司 | 制备重组玻尿酸酶的方法 |
| US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
| RS66849B1 (sr) | 2020-12-28 | 2025-06-30 | Bristol Myers Squibb Co | Kompozicije antitela i postupci njihove upotrebe |
| WO2022141232A1 (zh) * | 2020-12-30 | 2022-07-07 | 上海宝济药业有限公司 | 一种重组人透明质酸酶制剂及其应用 |
| AU2022376750A1 (en) * | 2021-10-29 | 2024-05-16 | Alteogen Inc. | Pharmaceutical composition comprising human hyaluronidase ph20 and drug |
| CN115820766B (zh) * | 2021-12-28 | 2024-11-12 | 华熙生物科技股份有限公司 | 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物 |
| AU2023281061A1 (en) | 2022-06-02 | 2024-12-05 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN120475959A (zh) * | 2022-12-23 | 2025-08-12 | 韩美药品株式会社 | 包含免疫活性白细胞介素2类似物缀合物的制剂 |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| CN117243852A (zh) * | 2023-11-01 | 2023-12-19 | 华熙生物科技股份有限公司 | 一种皮肤外用组合物及其用途 |
| CN119074669B (zh) * | 2024-06-21 | 2025-04-18 | 邢珺月 | 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| EP0162007A1 (de) * | 1984-04-18 | 1985-11-21 | Geriaco AG | Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris |
| EP0250119A3 (en) * | 1986-06-20 | 1990-04-18 | Vasocor | Atherosclerotic anti-idiotype antibody immunoassay and reagents |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6610292B2 (en) * | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
| AU1375199A (en) | 1997-11-12 | 1999-05-31 | Alza Corporation | Method for decreasing self-association of polypeptides |
| US6669663B1 (en) * | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
| US6559363B1 (en) * | 1999-07-05 | 2003-05-06 | Toyo Boseki Kabushiki Kaisha | Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants |
| WO2001046291A1 (en) | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| MXPA02011481A (es) * | 2000-05-19 | 2003-06-06 | Alcon Inc | Derivados de disulfuro que son utiles para el tratamiento de enfermedades alergicas. |
| US6902548B1 (en) * | 2001-03-19 | 2005-06-07 | Ed Schuler | Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments |
| US20030125234A1 (en) * | 2001-12-11 | 2003-07-03 | Middaugh Charles Russell | Alteration of protein stability |
| AU2004215912B2 (en) | 2003-02-26 | 2009-03-26 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| NZ542729A (en) * | 2003-04-23 | 2009-04-30 | Hexima Ltd | Isolation of a chymotrypsin, HpCh5, from Helicoveipa spp, characterised by its resistance to the proteinase inhibitors derived from Nicotiana alata |
| PL1740154T3 (pl) | 2004-03-12 | 2009-11-30 | Biodel Inc | Kompozycje insuliny o ulepszonym wchłanianiu |
| US20080124800A1 (en) * | 2004-03-31 | 2008-05-29 | Hexima Limited | Arabinogalactan Protein Compositions and Methods for Fostering Somatic Embryogenic Competence |
| WO2005118799A1 (en) * | 2004-04-15 | 2005-12-15 | Ista Pharmaceuticals, Inc. | Ovine hyaluronidase |
| US7976833B2 (en) * | 2005-10-14 | 2011-07-12 | Aspen Biomedical Research, Llc | Ophthalmic surgical irrigating solutions containing hyaluronidase and method for preventing post-operative intraocular pressure increases |
| JP2009512709A (ja) * | 2005-10-20 | 2009-03-26 | エムディーアールエヌエー，インコーポレイテッド | 速効型インスリンの経鼻投与 |
| EP2046284A1 (en) * | 2006-08-04 | 2009-04-15 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| IL186598A0 (en) | 2007-10-11 | 2008-11-03 | Mohammad Abdulrazik | Composition and method for the treatment or prevention of glaucoma and ocular hypertension |
| CN106906196A (zh) | 2008-03-06 | 2017-06-30 | 哈洛齐梅公司 | 可溶性透明质酸酶的大规模生产 |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| ES2724588T3 (es) | 2008-12-09 | 2019-09-12 | Halozyme Inc | Polipéptidos de PH20 soluble extendida y usos de los mismos |
| WO2011003822A2 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Insulinzubereitungen enthaltend methionin |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| AU2012271361B2 (en) * | 2011-06-17 | 2017-03-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme |
| BR112014016195A2 (pt) * | 2011-12-30 | 2020-10-27 | Halozyme, Inc. | variantes de polipeptídio ph20, formulações e usos das mesmas |
-
2012
- 2012-06-15 KR KR1020147001375A patent/KR20140043438A/ko not_active Ceased
- 2012-06-15 NZ NZ618331A patent/NZ618331A/en not_active IP Right Cessation
- 2012-06-15 CN CN201280039713.8A patent/CN103974715A/zh active Pending
- 2012-06-15 CN CN201610243096.3A patent/CN105797140B/zh active Active
- 2012-06-15 EA EA201400031A patent/EA201400031A1/ru unknown
- 2012-06-15 KR KR1020177027130A patent/KR101874401B1/ko active Active
- 2012-06-15 WO PCT/US2012/042816 patent/WO2012174478A2/en not_active Ceased
- 2012-06-15 CA CA2839511A patent/CA2839511C/en active Active
- 2012-06-15 EA EA201501068A patent/EA033472B1/ru not_active IP Right Cessation
- 2012-06-15 NZ NZ717728A patent/NZ717728A/en unknown
- 2012-06-15 JP JP2014516067A patent/JP2014518216A/ja active Pending
- 2012-06-15 BR BR112013032396A patent/BR112013032396A2/pt not_active IP Right Cessation
- 2012-06-15 EP EP12735366.2A patent/EP2720712B1/en active Active
- 2012-06-15 ES ES12735366.2T patent/ES2566549T3/es active Active
- 2012-06-15 MX MX2013014923A patent/MX340172B/es active IP Right Grant
- 2012-06-15 AU AU2012271359A patent/AU2012271359B2/en not_active Ceased
-
2013
- 2013-12-02 IL IL229749A patent/IL229749A0/en unknown
-
2016
- 2016-04-19 AU AU2016202472A patent/AU2016202472B2/en active Active
- 2016-10-12 JP JP2016200761A patent/JP6224802B2/ja active Active
-
2017
- 2017-06-06 JP JP2017111643A patent/JP2017197556A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201501068A1 (ru) | 2016-07-29 |
| CA2839511A1 (en) | 2012-12-20 |
| KR101874401B1 (ko) | 2018-07-04 |
| AU2012271359A1 (en) | 2014-01-09 |
| BR112013032396A2 (pt) | 2016-11-22 |
| JP2014518216A (ja) | 2014-07-28 |
| EP2720712A2 (en) | 2014-04-23 |
| IL229749A0 (en) | 2014-01-30 |
| CN105797140A (zh) | 2016-07-27 |
| JP2017197556A (ja) | 2017-11-02 |
| CN103974715A (zh) | 2014-08-06 |
| AU2012271359B2 (en) | 2016-05-19 |
| KR20170116173A (ko) | 2017-10-18 |
| EP2720712B1 (en) | 2016-03-02 |
| ES2566549T3 (es) | 2016-04-13 |
| WO2012174478A2 (en) | 2012-12-20 |
| EA201400031A1 (ru) | 2014-07-30 |
| JP2017036313A (ja) | 2017-02-16 |
| WO2012174478A9 (en) | 2013-05-30 |
| CN105797140B (zh) | 2020-08-11 |
| NZ717728A (en) | 2016-04-29 |
| AU2016202472B2 (en) | 2017-02-02 |
| MX2013014923A (es) | 2014-02-11 |
| NZ618331A (en) | 2016-04-29 |
| CA2839511C (en) | 2018-07-31 |
| EA033472B1 (ru) | 2019-10-31 |
| WO2012174478A3 (en) | 2013-04-11 |
| JP6224802B2 (ja) | 2017-11-01 |
| KR20140043438A (ko) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX340172B (es) | Formulaciones estables de una enzima degradadora de hialuronano. | |
| IL274798B (en) | Ph20 polypeptide variants, formulations and uses thereof | |
| AU2018256640A1 (en) | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | |
| AU2015317711B2 (en) | Compositions comprising recombinant Bacillus cells and another biological control agent | |
| EP2818543B8 (en) | Bacillus, hyaluronic acid enzyme, and uses thereof | |
| AU2012284088A8 (en) | Heterocyclic compounds and uses thereof | |
| NZ630805A (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| EP3750549A3 (en) | Composition for inducing proliferation or accumulation of regulatory t cells | |
| PH12015501470A1 (en) | Compositions and methods for the control of nematodes and soil borne diseases | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| PH12013501688A1 (en) | Treatment of amyotrophic lateral sclerosis using umbilical derived cells | |
| AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| MX349948B (es) | Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae. | |
| MX2019009229A (es) | Novedosas variantes enzimaticas que degradan la nicotina. | |
| AU2018256482A1 (en) | Antibodies Against Clostridium Difficile | |
| PH12014501369A1 (en) | Oral care compositions | |
| AU2011365688A8 (en) | Peptides with antimicrobial activity, drug compositions for the prophylaxis and treatment of animals, compositions for the prophylaxis and treatment of plants, uses of said peptides, and uses of Paenibacillus elgii ourofinensis extract | |
| PH12012501548A1 (en) | Compositions comprising sugar-cysteine products | |
| PH12015501131A1 (en) | Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states | |
| AU2012345659A8 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| HK1246653A1 (zh) | 奥那司酮延长释放组合物和方法 | |
| IN2015MN00102A (enExample) | ||
| MX2013005699A (es) | Composiciones de interferon-beta estables conservadas. | |
| IN2014MN02257A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |